Skip to content

Role of subcortical iron in Parkinson's disease, prodromal-depression, and dementia: Comparative links to anemias and osteoporosis.

Oct 2026 · Journal of Alzheimer's Disease · pp. 13872877261489296 · 0 citations · 63 references
Medicine

TL;DR

It is proposed that translational control of the iron-homeostatic protein α-synuclein (iron importer) could therapeutically normalize subcortical iron during PD progression.

Abstract

Three reports employing Mendelian randomization and quantitative susceptibility mapping from 41,581-patients in the UK biobank provide evidence to support that excess subcortical iron accumulation causally accelerates Parkinson's disease (PD). While subcortical iron was not a significant driver of Alzheimer's disease (AD), neural shrinkage and ferroptosis in grey matter featured in vascular dementia. Subcortical iron was changed in depression, anemia and osteoporosis patients. Since iron chelators were not beneficial to either AD or PD patients in clinical trials, we propose that translational control of the iron-homeostatic protein α-synuclein (iron importer) could therapeutically normalize subcortical iron during PD progression.

View source

Similar papers

Open access Sep 2026

Longitudinal Iron Changes in the Substantia Nigra of Early-Stage Parkinson's Disease.

BACKGROUND Progression of substantia nigra pars compacta (SNc) iron content in early-stage Parkinson's patients (PD) is poorly understood. OBJECTIVE To determine if nigral iron measured by quantitative susceptibility mapping (QSM) with zero-referencing    can track disease progression in early-stage PD. METHODS Thi...

G. Du, Christopher Sica, Sol de Jesus et al. · 0 citations
#data science Review Open access Oct 2026

Iron-related biomarkers and Lewy body dementia: a scoping review

Iron dysregulation is implicated in neurodegenerative disease pathophysiology, but its role in Lewy body dementia (LBD) remains poorly characterized. This review mapped iron-related measures across blood, cerebrospinal fluid (CSF), and brain compartments and evaluate their potential relevance as biomarkers in LBD....

Jessica L. Freeling, Lisa M. Mcfadden · 0 citations
Open access Oct 2026

Cortical Cholinergic Pathway Degeneration Reflects Cognitive Impairment and Dementia in Parkinson's Disease.

BACKGROUND Cognitive impairment is a prevalent and debilitating feature of Parkinson's disease (PD). Increasing evidence from postmortem and in vivo positron emission tomography imaging studies supports cholinergic dysfunction in PD. There is, however, little evidence regarding the influence of the structural integrity...

Nicola M. Slater, Daniel J. Myall, Reza Shoorangiz et al. · 0 citations
Review Open access Sep 2026

Cognition endpoints for Parkinson's disease: A roadmap for developing patient-focused assessment tools to accelerate drug development

Recommendations are made regarding necessary literature reviews, including qualitative data and related conceptual models, disease models including pathophysiology and neuropsychological profile, and clinical outcome assessment (COA) reviews, including content validity, psychometrics, and fitness-for-purpose.

Chris J. Edgar, Kathleen L. Poston, Cheryl D. Coon et al. · 0 citations
Sep 2026

Alzheimer's Co-Pathology Burden on Basal Forebrain Atrophy and Cognitive Impairment in Dementia with Lewy Bodies: A Cross-Sectional Pilot Study.

OBJECTIVE Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer's disease (AD), with significant pathological overlap between the two conditions. However, the impact of Alzheimer's co-pathology on basal forebrain (BF) atrophy and its relationship with neurodegeneration and...

Daniele Urso, Thomas Giannelli, B. Tafuri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.